The clinical relevance of molecular genetics in soft tissue sarcomas

Advances in Anatomic Pathology

Volumn 17, Issue 3, 2010, Pages 162-181

  Ordóñez, José Luis ^a   Osuna, Daniel ^a   García Domínguez, Daniel J ^a   Amaral, Ana Teresa ^a   Otero Motta, Ana Pastora ^a   MacKintosh, Carlos ^a   Sevillano, María Victoria ^a   Barbado, María Victoria ^a   Hernández, Teresa ^a   De Alava, Enrique ^a  

^a Centro de Investigacion del Cancer   (Spain)

Author keywords

Alveolar rhabdomyosarcoma; Bone soft tissue sarcomas; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Malignant fibrous histiocytoma; Mesenchymal tumors; Round cell myxoid liposarcoma; Sarcomagenesis; Sarcomas; Synovial sarcoma

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; AMG 479; ANTINEOPLASTIC AGENT; ELESCLOMOL; GEFITINIB; HORMONE RECEPTOR AFFECTING AGENT; HSP 70 VACCINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NVP AEW 541; PACLITAXEL; PAZOPANIB; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; RALOXIFENE; RAPAMYCIN; RIDAFOROLIMUS; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

ANGIOSARCOMA; BLASTOMA; CANCER GENE THERAPY; CANCER GENETICS; CANCER MODEL; CANCER RESEARCH; CHONDROSARCOMA; CHORDOMA; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CLEAR CELL CARCINOMA; CLEAR CELL SARCOMA; CLINICAL TRIAL; CONGENITAL FIBROSARCOMA; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; ENZYME INHIBITION; EWING SARCOMA; EXTRASKELETAL MYXOID CHONDROSARCOMA; FIBROMATOSIS; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GIANT CELL FIBROBLASTOMA; HEMANGIOPERICYTOMA; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MOLECULAR GENETICS; MYXOSARCOMA; NERVE SHEATH TUMOR; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHABDOMYOSARCOMA; RNA INTERFERENCE; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ANIMALS; HUMANS; MOLECULAR BIOLOGY; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 77951715996     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181d98cbf     Document Type: Review

References (208)

1. Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009;4:12-26.
2. Casali PG, Jost L, Sleijfer S, et al. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii89-ii93.
3. Ordonez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res. 2009;69:7140-7150.
4. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res. 2008;466:2156-2167.
5. Haldar M, Hancock JD, Coffin CM, et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007;11:375-388.
6. Haldar M, Hedberg ML, Hockin MF, et al. A CreER-Based Random Induction Strategy for Modeling Translocation- Associated Sarcomas in Mice. Cancer Res. 2009;69:3657-3664.
7. Keller C, Arenkiel BR, Coffin CM, et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperation of Ink4a/ ARF and Trp53 loss of function. Genes Dev. 2004;18:2614-2626.
8. Lin PP, Pandey MK, Jin F, et al. EWS-FLI1 Induces Developmental Abnormalities and Accelerates Sarcoma Formation in a Transgenic Mouse Model. Cancer Res. 2008;68: 8968-8975.
9. Perez-Losada J, Pintado B, Gutierrez-Adan A, et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene. 2000;19:2413-2422.
10. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162-165.
11. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146-151.
12. Maire G, Brown CW, Bayani J, et al. Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review. Cancer Genet Cytogenet. 2008;181:81-92.
13. Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 2003;63:4568-4576.
14. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10:1229-1234.
15. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETSfamily gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer. 1996;15:115-121.
16. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997;14:1159-1164.
17. Yamaguchi S, Yamazaki Y, Ishikawa Y, et al. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22) (p21;q12). Genes Chromosomes Cancer. 2005;43:217-222.
18. Mastrangelo T, Modena P, Tornielli S, et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene. 2000;19:3799-3804.
19. Wang L, Bhargava R, Zheng T, et al. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWSETV1 and EWS-FEV fusions. J Mol Diagn. 2007;9:498-509.
20. Szuhai K, Ijszenga M, de Jong D, et al. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res. 2009;15:2259-2268.
21. Ng TL, O'Sullivan MJ, Pallen CJ, et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn. 2007;9:459-463.
22. Mertens F, Wiebe T, Adlercreutz C, et al. Successful treatment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer. 2007;49:1015-1017.
23. Kawamura-Saito M, Yamazaki Y, Kaneko K, et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006;15:2125-2137.
24. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994;54: 2837-2840.
25. Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993;363:640-644.
26. Panagopoulos I, Hoglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 1996;12:489-494.
27. De Cecco L, Gariboldi M, Reid JF, et al. Gene expression profile identifies a rare epithelioid variant case of pleomorphic liposarcoma carrying FUS-CHOP transcript. Histopathology. 2005;46:334-341.
28. Clark J, Benjamin H, Gill S, et al. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene. 1996; 12:229-235.
29. Attwooll C, Tariq M, Harris M, et al. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17) (q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene. 1999;18:7599-7601.
30. Sjogren H, Wedell B, Meis-Kindblom JM, et al. Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res. 2000;60:6832-6835.
31. Hisaoka M, Ishida T, Imamura T, et al. TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer. 2004;40:325-328.
32. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4:341-345.
33. Antonescu CR, Nafa K, Segal NH, et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12:5356-5362.
34. Hallor KH, Mertens F, Jin Y, et al. Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2005;44:97-102.
35. Rossi S, Szuhai K, Ijszenga M, et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007;13:7322-7328.
36. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995;14:2333-2340.
37. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet. 1994;7:502-508.
38. Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst. 1999;91: 974-975.
39. Storlazzi CT, Mertens F, Mandahl N, et al. A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer. 2003;37:195-200.
40. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5:230-235. (Pubitemid 23330384)
41. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869-2872.
42. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004;64:5539-5545.
43. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2009;49:224-236.
44. Hosoi H, Kakazu N, Konishi E, et al. A novel PAX3 rearrangement in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 2009;189:98-104.
45. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95-98.
46. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6- NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184-187.
47. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48-57.
48. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Nat Acad Sci U S A. 2001;98:6348-6353.
49. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157:377-384.
50. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159:411-415.
51. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ranbinding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003;37:98-105.
52. Storlazzi CT, Mertens F, Nascimento A, et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet. 2003;12:2349-2358.
53. Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005;85:408-415.
54. Rabbitts TH. Commonality but diversity in cancer gene fusions. Cell. 2009;137:391-395.
55. Kovar H, Aryee D, Zoubek A. The Ewing family of tumors and the search for the Achilles' heel. Curr Opin Oncol. 1999; 11:275-284.
56. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998;16:1248-1255.
57. Lin PP, Brody RI, Hamelin AC, et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res. 1999;59:1428-1432.
58. Gerald WL, Ladanyi M, de Alava E, et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol. 1998;16:3028-3036.
59. Lee SB, Kolquist KA, Nichols K, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 1997;17:309-313.
60. Palmer RE, Lee SB, Wong JC, et al. Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell. 2002;2:497-505.
61. Antonescu CR, Argani P, Erlandson RA, et al. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer. 1998;83:1504-1521.
62. Subramanian S, West RB, Marinelli RJ, et al. The gene expression profile of extraskeletal myxoid chondrosarcoma. J Pathol. 2005;206:433-444.
63. Iwasaki H, Nabeshima K, Nishio J, et al. Pathology of softtissue tumors: daily diagnosis, molecular cytogenetics and experimental approach. Pathol Int. 2009;59:501-521.
64. Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46:1051-1060.
65. Antonescu CR, Tschernyavsky SJ, Woodruff JM, et al. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn. 2002;4: 44-52.
66. Aman P, Panagopoulos I, Lassen C, et al. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics. 1996;37:1-8.
67. Oda Y, Yamamoto H, Takahira T, et al. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J Pathol. 2005;207:410-421.
68. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3:113-117. (Pubitemid 23079791)
69. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1997;94:8047-8051.
70. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679.
71. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. New Engl J Med. 1998;338:153-160. (Pubitemid 28041862)
72. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYTSSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-140.
73. Oliveira AM, Fletcher CD. Molecular prognostication for soft tissue sarcomas: are we ready yet? J Clin Oncol. 2004;22: 4031-4034.
74. Hisaoka M, Okamoto S, Morimitsu Y, et al. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch. 1998;433:323-329.
75. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367-376.
76. Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequencespecific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005;65:8984-8992.
77. Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 2009;15:5696-5703.
78. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2- CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31: 1476-1489.
79. Ragazzini P, Gamberi G, Pazzaglia L, et al. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol. 2004;19:401-411.
80. Muller CR, Paulsen EB, Noordhuis P, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007;121:199-205.
81. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/ subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67: 6626-6636.
82. Snyder EL, Sandstrom DJ, Law K, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol. 2009;218:292-300.
83. Kotiligam D, Lazar AJ, Pollock RE, et al. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol. 2008;23:117-126.
84. Carlson JW, Fletcher CD. Immunohistochemistry for b-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509-514.
85. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the b-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518-1527.
86. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev. 2008;8:915-928.
87. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol. 2008;20:419-427.
88. Martins AS, Ordonez JL, Garcia-Sanchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 2008;68:6260-6270.
89. Herrero-Martin D, Osuna D, Ordonez JL, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer. 2009;101:80-90.
90. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets. 2009;10:923-936.
91. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009;28:3009-3021.
92. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008;68:8039-8048.
93. Huang F, Greer A, Hurlburt W, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009;69:161-170.
94. Nagayama S, Katagiri T, Tsunoda T, et al. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002;62:5859-5866. (Pubitemid 35204746)
95. Sato H, Hasegawa T, Kanai Y, et al. Expression of cadherins and their undercoat proteins (a-, b-, and g-catenins and p120) and accumulation of b-catenin with no gene mutations in synovial sarcoma. Virchows Arch. 2001;438:23-30.
96. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003;163:691-700.
97. Uren A, Wolf V, Sun YF, et al. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer. 2004;43:243-249.
98. Matushansky I, Hernando E, Socci ND, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest. 2007;117:3248-3257.
99. Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with b-catenin, APC, and GSK3b. Science (NY). 1998;280:596-599.
100. He X. A Wnt-Wnt situation. Dev Cell. 2003;4:791-797.
101. Liu C, Li Y, Semenov M, et al. Control of b-catenin phosphorylation/ degradation by a dual-kinase mechanism. Cell. 2002;108:837-847.
102. Saito T, Oda Y, Sakamoto A, et al. APC mutations in synovial sarcoma. J Pathol. 2002;196:445-449.
103. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005;65:9226-9235.
104. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301-1307.
105. Linn SC, West RB, Pollack JR, et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol. 2003;163:2383-2395.
106. Geryk-Hall M, Hughes DP. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep. 2009;11:446-453.
107. Torchia EC, Boyd K, Rehg JE, et al. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol. 2007;27:7918-7934.
108. Hu-Lieskovan S, Zhang J, Wu L, et al. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005;65:4633-4644.
109. Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008;68: 2176-2185.
110. Suva ML, Riggi N, Stehle JC, et al. Identification of Cancer Stem Cells in Ewing's Sarcoma. Cancer Res. 2009;69: 1776-1781.
111. Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas. Cancer. 1971;28:461-466.
112. Aigner T, Dertinger S, Neureiter D, et al. De-differentiated chondrosarcoma is not a 'de-differentiated' chondrosarcoma. Histopathology. 1998;33:11-19.
113. Rywlin AM. Chondrosarcoma of bone with ''dedifferentiation''. Hum Pathol. 1982;13:963-964.
114. Tetu B, Ordonez NG, Ayala AG, et al. Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). II. An immunohistochemical and electron microscopic study. Cancer. 1986;58:287-298. (Pubitemid 16058604)
115. Bridge JA, DeBoer J, Travis J, et al. Simultaneous interphase cytogenetic analysis and fluorescence immunophenotyping of dedifferentiated chondrosarcoma. Implications for histopathogenesis. Am J Pathol. 1994;144:215-220.
116. Bovee JV, Cleton-Jansen AM, Rosenberg C, et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol. 1999;189:454-462.
117. Coughlan B, Feliz A, Ishida T, et al. p53 expression and DNA ploidy of cartilage lesions. Hum Pathol. 1995;26:620-624.
118. Dobashi Y, Sugimura H, Sato A, et al. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Diagn Mol Pathol. 1993;2:257-263.
119. Yamaguchi T, Toguchida J, Wadayama B, et al. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res. 1996;16:2009-2015.
120. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010;456:201-217.
121. Sanerkin NG. Primary leiomyosarcoma of the bone and its comparison with fibrosarcoma. Cancer. 1979;44:1375-1387.
122. Yamashina M. Primary leiomyosarcoma in the breast. Jpn J Clin Oncol. 1987;17:71-77.
123. Wick MR, Young RH, Malvesta R, et al. Prostatic carcinosarcomas. Clinical, histologic, and immunohistochemical data on two cases, with a review of the literature. Am J Clin Pathol. 1989;92:131-139.
124. Ishiwata I, Ishiwata C, Soma M, et al. Histogenesis of carcinosarcoma and establishment of leiomyosarcoma cell line (HTMMT) derived from human uterine carcinosarcoma. Hum Cell. 2004;17:131-137.
125. Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol. 1996;20:277-285.
126. Jin Z, Ogata S, Tamura G, et al. Carcinosarcomas (malignant Mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol. 2003;22:368-373.
127. Hernando E, Charytonowicz E, Dudas ME, et al. The AKTmTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13:748-753.
128. Engstrom K,Willen H, Kabjorn-Gustafsson C, et al. Themyxoid/ round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol. 2006;168:1642-1653.
129. Goransson M, Andersson MK, Forni C, et al. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene. 2009;28:270-278.
130. Riggi N, Cironi L, Provero P, et al. Expression of the FUSCHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006;66:7016-7023.
131. Domoto H, Hosaka T, Oikawa K, et al. TLS-CHOP target gene DOL54 expression in liposarcomas and malignant fibrous histiocytomas. Pathol Int. 2002;52:497-500.
132. Boland GM, Perkins G, Hall DJ, et al. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cellular Biochem. 2004; 93:1210-1230.
133. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits b-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006;4:e115.
134. Going JJ, Lumsden AB, Anderson TJ. A classical osteogenic sarcoma of the breast: histology, immunohistochemistry and ultrastructure. Histopathology. 1986;10:631-641.
135. Remadi S, Doussis-Anagnostopoulu I, Mac Gee W. Primary osteosarcoma of the breast. Pathol Res Pract. 1995;191:471- 474; discussion 475-477.
136. Tazi H, Karmouni T, Ouali M, et al. Osteosarcoma of the testis. Int J Urol. 2006;13:323-324.
137. Keller C, Hansen MS, Coffin CM, et al. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev. 2004;18: 2608-2613.
138. Odelberg SJ, Kollhoff A, Keating MT. Dedifferentiation of mammalian myotubes induced by msx1. Cell. 2000;103: 1099-1109.
139. Tiffin N, Williams RD, Shipley J, et al. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer. 2003;89:327-332.
140. Renwick PJ, Reeves BR, Dal Cin P, et al. Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp11.2, with implications for the histologic sub-classification of synovial sarcoma. Cytogenet Cell Genet. 1995;70:58-63.
141. de Torres C, Cardesa TM, Rodriguez-Perales S, et al. Epithelioid sarcoma with SYT-SSX1 fusion gene expression: molecular and cytogenetic analysis. Cancer Genet Cytogenet. 2005;162:50-56.
142. Saito T, Nagai M, Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Res. 2006; 66:6919-6927.
143. Ono H, Yoshikawa H, Ueda T, et al. Expression of smooth muscle calponin in synovial sarcoma. Sarcoma. 1999; 3:107-113.
144. Gonzalez I, Vicent S, de Alava E, et al. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med (Berlin, Germany). 2007;85:1015-1029.
145. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006;12:3532-3540.
146. Vormoor J, Baersch G, Decker S, et al. Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice. Pediatr Res. 2001;49:332-341.
147. Scotlandi K, Benini S, Manara MC, et al. Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res. 2000; 18:959-966.
148. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res. 2007;13: 1322-1330.
149. Castillero-Trejo Y, Eliazer S, Xiang L, et al. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res. 2005;65:8698-8705.
150. Riggi N, Cironi L, Provero P, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005;65:11459-11468.
151. Fisher JL, Mackie PS, Howard ML, et al. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res. 2001;7:1654-1660.
152. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005;116:458-463.
153. Dass CR, Ek ET, Contreras KG, et al. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis. 2006;23:367-380.
154. Almog N, Henke V, Flores L, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. 2006;20:947-949.
155. Riggi N, Cironi L, Provero P, et al. Expression of the FUSCHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006;66:7016-7023.
156. Garg V, Zhang W, Gidwani P, et al. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res. 2007;13: 5446-5454.
157. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928-940.
158. Izbicka E, Campos D, Marty J, et al. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res. 2006;26:1983-1988.
159. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nature Rev. 2007;7:645-658.
160. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/ TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene. 2000;19:6015-6022.
161. Forster A, Pannell R, Drynan LF, et al. The invertor knockin conditional chromosomal translocation mimic. Nat Methods. 2005;2:27-30.
162. Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell. 1996;85:853-861.
163. Forster A, Pannell R, Drynan LF, et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell. 2003;3:449-458.
164. Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63-74.
165. Beltinger C, Debatin KM. Murine models for experimental therapy of pediatric solid tumors with poor prognosis. Int J Cancer. 2001;92:313-318.
166. Khanna C, Prehn J, Yeung C, et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis. 2000;18:261-271.
167. Ek ET, Dass CR, Choong PF. Commonly used mouse models of osteosarcoma. Crit Rev Oncol/Hematol. 2006;60:1-8.
168. Nakamura Y, Yamada N, Ohyama H, et al. Effect of interleukin-18 on metastasis of mouse osteosarcoma cells. Cancer Immunol Immunother. 2006;55:1151-1158.
169. Manara MC, Baldini N, Serra M, et al. Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone. 2000;26:215-220.
170. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis. 1999;17:501-506.
171. Jia SF, Worth LL, Turan M, et al. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine. Anticancer Drugs. 2002;13:155-161.
172. Worth LL, Jia SF, Zhou Z, et al. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res. 2000;6:3713-3718.
173. Ek ET, Dass CR, Choong PF. Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Ther. 2006; 5:1641-1646.
174. Ek ET, Dass CR, Contreras KG, et al. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis. 2007;24:93-106.
175. Dass CR, Ek ET, Choong PF. Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol. 2007;133:193-198.
176. Luu HH, Kang Q, Park JK, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005;22:319-329.
177. Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res. 2005;65: 7530-7532.
178. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med. 1998;4:619-622.
179. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med. 2002;8:1276-1280.
180. Fleischmann A, Jochum W, Eferl R, et al. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell. 2003;4: 477-482.
181. Nanni P, Nicoletti G, De Giovanni C, et al. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res. 2003;63:2728-2732.
182. Tsumura H, Yoshida T, Saito H, et al. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006; 25:7673-7679.
183. Lauwers GY, Black-Schaffer S, Salto-Tellez M. Molecular pathology in contemporary diagnostic pathology laboratory: an opinion for the active role of surgical pathologists. Am J Surg Pathol. 2010;34:115-117.
184. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27:5800-5807.
185. Subbiah V, Anderson P, Lazar AJ, et al. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009;10:126-140.
186. Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13: 5034-5040.
187. Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther. 2008;7:890-896.
188. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-3140.
189. Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol. 2010;21:208-215.
190. Verweij J. Soft tissue sarcoma trials: one size no longer fits all. J Clin Oncol. 2009;27:3085-3087.
191. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866-873.
192. Heinrich MC,McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006; 24:1195-1203.
193. Hensley ML, Sill MW, Scribner DR Jr, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009;115:460-465.
194. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154-3160.
195. Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.
196. Ordonez JL, Martins AS, Osuna D, et al. Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol. 2008;25:304-316.
197. Hashemi SM, Hassan ZM, Soudi S, et al. Evaluation of antitumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice. Int Immunopharmacol. 2007;7:920-927.
198. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008;26:5583-5588.
199. Liebig C, Wilks JA, Feig BW, et al. The role of angiocidin in sarcomas. Cancer. 2009;115:5251-5262.
200. Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005;24:6201-6212.
201. Miyagawa Y, Okita H, Itagaki M, et al. EWS/ETS regulates the expression of the Dickkopf family in Ewing family tumor cells. PLoS ONE. 2009;4:e4634.
202. Gazitt Y, Kolaparthi V, Moncada K, et al. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/ MAPK/Wnt pathways. Int J Oncol. 2009;34:551-561.
203. Filion C, Motoi T, Olshen AB, et al. The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol. 2009; 217:83-93.
204. Canner JA, Sobo M, Ball S, et al. MI-63: a novel smallmolecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wildtype p53. Br J Cancer. 2009;101:774-781.
205. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126-3132.
206. Liu S, Cheng H, Kwan W, et al. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther. 2008;7: 1751-1761.
207. Lipskar AM, Glick RD, Huang J, et al. Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. J Pediatr Surg. 2009;44:1139-1146; discussion 1146.
208. Scotlandi K, Perdichizzi S, Bernard G, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer. 2006;42:91-96.